Bone Marrow Transplantation最新文献

{"title":"Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients.","authors":"Anne B Verbeek, Erik G J von Asmuth, Erik B van den Akker, Anja M Jansen-Hoogendijk, Marco W Schilham, Arjan C Lankester, Gertjan Lugthart, Alexander B Mohseny, Emilie P Buddingh","doi":"10.1038/s41409-025-02583-5","DOIUrl":"https://doi.org/10.1038/s41409-025-02583-5","url":null,"abstract":"<p><p>In this explorative study we aimed to identify inflammatory serum proteins measured before allogeneic hematopoietic stem cell transplantation (HSCT) that are associated with acute Graft-versus-Host Disease (aGvHD) and mortality in pediatric HSCT recipients. We measured 28 inflammatory serum proteins in 384 pediatric patients (2010-2022) with malignant (30%) and non-malignant (70%) indications for allogeneic HSCT. A sample before the start of the conditioning (T1) was included, as well as a sample on the day of HSCT (T2). For patients who developed aGvHD we also included a sample at the time of diagnosis, before initiation of systemic treatment (TP-GvHD). Associations with aGvHD, steroid-refractory aGvHD, non-relapse mortality (NRM) and overall survival (OS) were analyzed using robust (cause-specific) Cox models. At T1, TNFR1, sIL-2Rα and TNFR2 were among the most strongly associated proteins for the development of aGvHD. Multiple inflammatory proteins, such as CXCL16, TNFR1 and SCF at T1 were highly associated with NRM and OS. At TP-GvHD, ST2 levels were significantly associated with the development of steroid-refractory aGvHD and NRM. This study shows that inflammatory serum protein levels before HSCT are associated with aGvHD and mortality and lays the groundwork for further validation and use in risk-adapted therapy for pediatric HSCT recipients.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growing adoption of pharmacologic maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf of the EBMT acute leukemia working party.","authors":"Iman Abou Dalle, Myriam Labopin, Irma Khvedelidze, Frédéric Baron, Eolia Brissot, Gesine Bug, Jordi Esteve, Sebastian Giebel, Norbert-Claude Gorin, Francesco Lanza, Arnon Nagler, Zina Peric, Simona Piemontese, Annalisa Ruggeri, Jaime Sanz, Bipin Savani, Christoph Schmid, Roni Shouval, Alexandros Spyridonidis, Jurjen Versluis, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty","doi":"10.1038/s41409-025-02576-4","DOIUrl":"https://doi.org/10.1038/s41409-025-02576-4","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.","authors":"Carmen Martínez, Irma Khvedelidze, Mathilde Fekom, Benedicte Deau Fischer, Amira Marouf, Hervé Ghesquières, Luc-Mathieu Fornecker, Francesco Merli, Piero Maria Stefani, Fulvio Massaro, Barbara Botto, Burhan Ferhanoğlu, Olga Meltem Akay, Murat Özbalak, Manuel Espeso de Haro, Samuel Romero, Jaques-Emmanuel Galimard, Bertram Glass, Ali Bazarbachi, Anna Sureda","doi":"10.1038/s41409-025-02568-4","DOIUrl":"https://doi.org/10.1038/s41409-025-02568-4","url":null,"abstract":"<p><p>We evaluated brentuximab vedotin (BV) as maintenance therapy after autologous stem cell transplantation (ASCT) in 353 patients with relapsed/refractory Hodgkin lymphoma (HL). Of these, 52.6% received BV prior to ASCT. The five-year overall survival (OS) and progression-free survival (PFS) from the start of BV maintenance were 85.1% and 69.9%, respectively. Multivariable analysis revealed that age at ASCT (HR 1.17, P = 0.037), disease status (HR 3.61, P = 0.002), and BV treatment before ASCT (HR 0.40, P = 0.033) significantly impacted OS. Disease status at ASCT was the only factor significantly associated with PFS (HR 3.09, p < 0.001) and relapse risk (HR 3.33, p < 0.001). Although a trend toward improved PFS (HR 0.59, p = 0.053) and lower relapse risk (HR 0.57, p = 0.051) was observed in patients treated with BV before ASCT, the data were not statistically significant. Patients in complete remission (CR) at ASCT showed similar 2-year OS (94.6% vs. 99.2%, P = 0.3) and PFS (84.6% vs. 89%, P = 0.3) regardless of BV pre-transplant. In those not in CR, OS (83.1% vs. 93.6%, P = 0.076) and PFS (51.5% vs. 75.3%, P = 0.039) were higher in those previously treated with BV. This large study emphasizes BV maintenance post-ASCT, even in patients pre-treated with BV, ang highlights disease status as a key prognostic factor.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.","authors":"Peter Dreger, Sairah Ahmed, Ali Bazarbachi, Sascha Dietrich, Timothy S Fenske, Nilanjan Ghosh, Olivier Hermine, Mehdi Hamadani","doi":"10.1038/s41409-025-02599-x","DOIUrl":"https://doi.org/10.1038/s41409-025-02599-x","url":null,"abstract":"<p><p>Cellular therapies have been cornerstones of the treatment of mantle cell lymphoma (MCL) for decades and have helped to improve the outcome of this formerly very unfavourable B-cell lymphoma considerably. Current established roles of cellular therapies include autologous hematopoietic cell transplantation (HCT) as part of first-line therapy, chimeric antigen receptor-engineered T-cells (CART) for relapsed/refractory MCL, and allogeneic HCT for settings in which CARTs have failed or are unavailable. Therapeutic innovations have recently entered the MCL treatment landscape and are moving upstream in treatment algorithms, challenging the existing management principles. The purpose of this paper is to give some guidance regarding how to best use cellular therapies in this increasingly complex environment. Due to differences in CART labels, available non-cellular treatment options, and philosophy between the American and the European health systems, we found it reasonable to contrast the American and European perspectives on defined standard scenarios, which are often overlapping but show discrepancies in some important aspects.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey.","authors":"Niklas Brehm, Francesca Biavasco, Johannes Clausen, Johannes Jung, Kristina Maas-Bauer, Ralph Wäsch, Mareike Verbeek, Christoph Nuernbergk, Gabriele Ihorst, Stuart Seropian, Jürgen Finke, Lohith Gowda, Rakefet Sidlik Muskatel, Régis Peffault de Latour, Gérard Socie, Claudia Wehr, David Michonneau, Robert Zeiser","doi":"10.1038/s41409-025-02586-2","DOIUrl":"https://doi.org/10.1038/s41409-025-02586-2","url":null,"abstract":"<p><p>Intestinal glucocorticoid-refractory (SR) acute (a) graft-versus-host disease (GVHD) causes high non-relapse mortality (NRM) in patients after allogeneic hematopoietic cell transplantation (allo-HCT). Recent preclinical data indicate that acute GVHD causes a loss of intestinal neuroendocrine L-cells leading to reduced levels of glucagon-like peptide-2 (GLP-2). GLP-2 substitution improved GVHD severity and increased Paneth cells and intestinal stem cells in mice. This motivated us to treat patients with refractory intestinal aGHVD using the GLP-2-analogon teduglutide. In this retrospective multicenter survey, 17 patients received teduglutide as salvage-therapy for SR-intestinal aGVHD. The best response (CR or PR) at any time point during and after treatment was 64.7% (11/17) including 41.2% (7/17) CR and 23.5% (4/17) PR. At a median follow-up of 28 weeks after teduglutide 10/17 patients are alive. Most patients experienced an increase of the albumin serum level within 2 months after the first teduglutide dose, including patients who clinically did not respond to teduglutide treatment. No specific teduglutide-related toxicity was observed. Our retrospective analysis suggests that teduglutide is safe and has activity in a fraction of patients with intestinal SR-aGVHD, which needs validation in a prospective trial.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of haplo-HSCT with post-transplant cyclophosphamide in pediatric hematologic malignancies: a study on behalf of SFGM-TC and SFCE.","authors":"Charlotte Calvo, Cléo Hautefeuille, Loïc Vasseur, Florian Chevillon, Charlotte Nazon, Benedicte Bruno, Marc Ansari, Arthur Sterin, Anne Sirvent, Audrey Grain, Marie Angoso, Virginie Gandemer, Pascale Schneider, Carine Halfon-Domenech, Pierre-Simon Rohrlich, Cécile Pochon, Catherine Paillard, Stephanie Nguyen Quoc, Nicole Raus, Marion Strullu, Françoise Méchinaud, Nathalie Dhedin, Jean-Hugues Dalle","doi":"10.1038/s41409-025-02584-4","DOIUrl":"https://doi.org/10.1038/s41409-025-02584-4","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias.","authors":"Abdullah Karakus, Tayfur Toptas, Mehmet Sinan Dal, Ali Durdu, Ugur Hatipoglu, Merve Apaydin Kayer, Ipek Yonal Hindilerden, Tarik Onur Tiryaki, Dicle Iskender, Bahar Uncu Ulu, Tugce Nur Yigenoglu, Mehmet Ali Erkurt, Turgay Ulas, Fevzi Altuntas","doi":"10.1038/s41409-025-02564-8","DOIUrl":"https://doi.org/10.1038/s41409-025-02564-8","url":null,"abstract":"<p><p>In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse and overall survival rates in patients using myeloablative/reduced intensity conditioning regimens with posttransplant cyclophosphamide (PTCy) 25 mg/kg x2 with Anti-T lymphocyte Globulin (ATLG) (n = 29) and PTCy 50 mg/kg x2 doses (n = 41) in patients with acute leukemias. Matched related, matched unrelated, 1 mismatched unrelated, and haploidentical donors were selected for the patients. Platelet (median 11 vs 17 days) and neutrophil (median 14 vs 15 days) engraftment times were shorter in ATLG+ PTCy25 treated patients (both p < 0.05); veno-occlusive disease rates, graft failure and poor graft functions were similar between the two approaches (all p > 0.05); cumulative incidences of grade II-IV aGVHD at +100 days, grade III-IV aGVHD at +100 days, and grade II-IV cGVHD at 1-year were comparable between ATLG+PTCy25 and PTCy50 groups (all p > 0.05). Cumulative incidences of relapse and non-relapse mortality at 1-year were similar in two cohorts (both p > 0.05). PTCy50 was associated with a statistically significant benefit in terms of GVHD-free/relapse-free survival (GRFS) at 1-year (p = 0.03). Median GRFS was 115 (95% CI: 42-214) days and 248 (95% CI: 151-not reached) days, respectively [HR was 0.51 (0.28-0.95), p = 0.03; GRFS at 1-year was 20.7% vs 44.3%, respectively]. However, the groups were comparable in terms of PFS and OS. Median PFS was 332 days (95% CI: 182 days-not reached) for ATLG+PTCy25 group. It was not reached (95% CI: 210 days-not reached) for the patients who received PTCy50. Median OS was not reached in either ATLG+PTCy25 (95% CI: 191 days-not reached) or PTCy50 groups (Log rank = 0.42). Our study showed that lowering PTCy dose with ATLG seems to accelerate platelet and neutrophil engraftment rates; confers similar survival and relapse rates, similar acute and chronic GVHD frequency despite increased GRFS at 1-year.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in allogeneic hematopoietic stem cell transplantation for Fanconi anemia.","authors":"M Gonzalez Vicent, A Peretó, J Zubicaray, B Molina, S Vinagre, E Sebastián, J Iriondo, A Castillo, L Abad, A Sanz, G Lopez de Hontanar, M Ramirez, J Sevilla, M A Diaz","doi":"10.1038/s41409-025-02591-5","DOIUrl":"https://doi.org/10.1038/s41409-025-02591-5","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.","authors":"Matthew A Bergens, Yen P Lowder, Yan Li, Ernaya J Johnson, Hilary M Winthrop, Amy T Bush, Angela Xiong, Lauren Hill, Isabella Gorski, Bethany Weaver, S Yousuf Zafar, Edwin P Alyea, Nelson J Chao, Taewoong Choi, Cristina Gasparetto, Sanghee Hong, Mitchel E Horwitz, Chenyu Lin, Gwynn D Long, Richard D Lopez, Sendhilnathan Ramalingam, Stefanie Sarantopoulos, Keith M Sullivan, Anthony D Sung","doi":"10.1038/s41409-025-02587-1","DOIUrl":"https://doi.org/10.1038/s41409-025-02587-1","url":null,"abstract":"<p><p>Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effects, leading to weight loss and malnutrition. We hypothesize that pre-HSCT FI increases the risk of malnutrition, requiring nutrition support, and adverse psychosocial outcomes. Between February 2018 and August 2022, 284 patients were screened before HSCT for FI. 71 (25%) were excluded due to missing data. Of the remaining 213, 20 (9.4%) reported pre-HSCT FI. Patients with FI were more likely to develop malnutrition during HSCT (70% vs. 45.1%, p = 0.034) and need total parenteral nutrition compared to those without FI (65% vs. 34.2%, p = 0.013). Patients with FI also were more likely to screen positive for depression (40% vs. 10.4%, p = 0.002) and financial toxicity (75% vs. 25%, p < 0.001). There were no significant differences in survival or other secondary outcomes. Our study demonstrates that pre-HSCT FI significantly increases likelihood of malnutrition, the need for total parenteral nutrition, and adverse psychosocial outcomes in HSCT patients. These findings highlight the critical importance of early identification and interventions to address FI as part of comprehensive cancer care.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.","authors":"Jayastu Senapati, Guillermo Garcia-Manero, Courtney D DiNardo, Indraneel Deshmukh, Gautam Borthakur, Tapan M Kadia, Elias Jabbour, Nicholas J Short, Hussein A Abbas, Naveen Pemmaraju, Nitin Jain, Fadi G Haddad, Ghayas C Issa, Abhishek Maiti, Elizabeth Shpall, Uday Popat, Sanam Loghavi, Guilin Tang, Musa Yilmaz, Yesid Alvarado, Guillermo Montalban-Bravo, Farhad Ravandi, Hagop M Kantarjian, Naval G Daver","doi":"10.1038/s41409-025-02590-6","DOIUrl":"https://doi.org/10.1038/s41409-025-02590-6","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}